BiomX Q4 2023 Earnings Report $0.62 +0.05 (+8.89%) (As of 12/20/2024 04:33 PM ET) Earnings HistoryForecast BiomX EPS ResultsActual EPS-$0.08Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ABiomX Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ABiomX Announcement DetailsQuarterQ4 2023Date4/3/2024TimeN/AConference Call ResourcesPHGE Earnings History 2025 could be “worse than the dot-com bust”, says man who predicted 2008 banking crisis (Ad)Dan is sharing his latest work with the public. Because what he's tracking right now, he says, is too serious to keep private.Click here to see Dan's full warning to the public. BiomX Earnings HeadlinesBiomX Inc. Receives Notice of Compliance with NYSE American Continued Listing StandardsDecember 16, 2024 | markets.businessinsider.comBiomX Inc (PHGE) Q3 2024 Earnings Call Highlights: Strong Net Income Amid Rising ExpensesNovember 16, 2024 | finance.yahoo.com2025 could be “worse than the dot-com bust”, says man who predicted 2008 banking crisisDan is sharing his latest work with the public. Because what he's tracking right now, he says, is too serious to keep private.December 22, 2024 | Stansberry Research (Ad)BiomX Inc: Promising Clinical Advancements and Strong Financial Position Justify Buy RatingNovember 15, 2024 | markets.businessinsider.comBiomX Inc. Reports Q3 2024 Financial TurnaroundNovember 15, 2024 | markets.businessinsider.comBiomX announces mandatory unit separationOctober 16, 2024 | finance.yahoo.comSee More BiomX Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like BiomX? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BiomX and other key companies, straight to your email. Email Address About BiomXBiomX (NYSEAMERICAN:PHGE), a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.View BiomX ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
